403 ‒ Peptides: separating scientific promise from marketing hype

Peter Attia uses a short-format episode to separate peptide science from what he describes as “rampant commercialisation” in the grey-market wellness ecosystem. He defines peptides as short amino-acid chains and argues the label “peptide” is a chemical description rather than a safety or efficacy stamp, noting that some peptides (such as insulin and GLP-1 agonists) are among the most consequential modern drugs.

Attia outlines a five-part framework for evaluating any drug: plausibility of mechanism, evidence of meaningful human benefit, clarity on dosing/pharmacokinetics and safety, individualised risk-benefit trade-offs, and whether better-characterised alternatives exist. He then applies the framework to BPC-157, calling it a “poster child” for hype: he claims the compound’s provenance and primary mechanism are unclear, that most supportive studies are pre-clinical and concentrated in a small research network with commercial interests, and that published peer-reviewed human randomised trials showing accelerated healing are absent. He also warns that the pro-angiogenic mechanisms sometimes invoked by proponents could, in principle, raise safety questions, while emphasising this is not proof of carcinogenicity.

Attia contrasts biologically active peptides such as CJC-1295—capable of raising growth hormone/IGF-1—with the need for patient-relevant outcomes, arguing biomarker changes do not automatically translate into functional benefit. He criticises reliance on testimonials, highlighting regression to the mean, concurrent lifestyle changes, placebo effects and reporting bias, and he explains what FDA-style development adds (manufacturing controls, dosing data, safety characterisation and surveillance) versus what is lost when bypassing it.

• Attia says “peptide” is not a proxy for safety or effectiveness; it is a chemical category that includes both major medicines and poorly evidenced products.
• He proposes a five-question framework: mechanism, human outcomes evidence, safety/PK/dosing, individual risk-benefit, and better-characterised alternatives.
• On BPC-157, Attia claims the origin and mechanism are unclear and argues there are no published peer-reviewed human RCTs demonstrating accelerated healing.
• He argues testimonials are not reliable evidence because injuries often improve naturally, people change multiple behaviours at once, placebo effects can be large, and reporting bias is common.
• He says biologic activity (e.g., raising GH/IGF-1 with CJC-1295) does not necessarily imply meaningful improvements in strength, recovery, function, or quality of life.
• He argues FDA-style development primarily provides information: defined benefits in defined populations, dosing and pharmacokinetics, safety monitoring, and manufacturing standards.
• He disputes the claim that peptides are ignored because they cannot be patented, asserting companies can patent modified analogues, processes, and uses, and citing patents related to BPC-157.